This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
and an investigator in the VIVID study , which contributed to the device’s FDA approval – successfully used the Duo Venous Stent System for the first time outside of a clinical trial. Duo Hybrid has a distinct integrated design that combines multiple zones of differing mechanical properties into a single stent [3].
In this phenomenon, a thrombus forms within the lumen of the stent graft component of the frozen elephant trunk prosthesis and puts the patient at risk for downstream embolization with visceral or lower limb ischemia. The long-term efficiency of these prophylactic and therapeutic measures has yet to be proven.
Smits and a distinguished team of international researchers, the trial compares the performance of SMT's biodegradable-polymer sirolimus-eluting Supraflex Cruz stent with the biodegradable-polymer Ultimaster Tansei * stent in patients with high bleeding risk (HBR) undergoing abbreviated dual antiplatelet therapy (DAPT).
BACKGROUND:In patients with post-thrombotic syndrome, stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stentthrombosis is particularly increased during the first 6 months after intervention.
In the DA+DCB arm, there was a trend toward higher stent-free patency through 12 months (79.1% versus 68.1%, · P=0.09) and a significantly lower provisional stenting rate (9.5% 3,4 bailout stenting rates were low following atherectomy in both observational studies (9.3% versus 21.1%, P =0.014). 3 · One-year rates of TLR (16.6%
"Clinicians need better tools to guide decision making on the choice of antiplatelet therapy in coronary artery disease patients, particularly after coronary stenting. The Prolocor pFCG test will be an important asset as we tailor antiplatelet therapies to balance thrombotic and bleeding risk" said Dominick J.
BackgroundThe left subclavian artery (LSA) can be intentionally covered by a stent graft to acquire adequate landing zones for a proximal entry tear near the LSA during thoracic endovascular aortic repair (TEVAR). The Castor single-branched stent graft is designed to treat type B aortic dissection (TBAD) to retain the LSA during TEVAR.
Subjects with type 2 diabetes (T2D) have a higher risk of in-stent restenosis and stentthrombosis. The activation of the glucagon-like peptide-1 receptor (GLP-1R) has been suggested to induce several effects.
All patients had headache, and funduscopic examination demonstrated papilledema for all patients. All patients had headache, and funduscopic examination demonstrated papilledema for all patients. All patients had headache, and funduscopic examination demonstrated papilledema for all patients.
XIENCE Skypoint™ stent was deployed within the left vertebral artery (V4 segment) with restoration of flow preceded by eptifibatide drip (Fig 2). Repeat CTA at six months showed patent left vertebral and basilar arteries.ConclusionRescue stenting using DES may be a successful and safe therapeutic intervention for challenging failed MT.
BackgroundBehcet's disease (BD) is a systematic vasculitis that affects vessels with various sizes, presenting as venous thrombosis and arterial pseudoaneurysms.
These results were driven mainly by the reduction in repeat vessel revascularisation, stroke and stentthrombosis. Conclusion Colchicine significantly reduced the risk of MACE in patients with CAD who underwent PCI, mostly in the reduction of repeat vessel revascularisation, stroke and stentthrombosis.
(Charles Darwin) Despite being proposed more than three decades ago, dual antiplatelet therapy has become a cornerstone of medical treatment for patients suffering from acute coronary syndrome after the introduction of bare metal stents to overcome the risk of restenosis and stentthrombosis associated with such devices.
The near-immediate or instant feedback learning process by which the heart responds to any new invasive procedural variation facilitates each new change; be it drug-eluting stent, drug-coated balloon, or both in different combinations and permutations.
Previous medical interventions included a spectrum of procedures, including catheter-directed thrombectomy for popliteal artery aneurysms with thrombosis, vascular bypass grafting for cerebral-anterior communicating artery aneurysms and arch replacement and stent implantation for aortic dissecting aneurysms.
Publication date: Available online 17 July 2024 Source: The American Journal of Cardiology Author(s): Gani Bajraktari, Ibadete Bytyçi, Genc Abdyli, Pranvera Ibrahimi, Artan Bajraktari, Rona Karahoda, Shpend Elezi, Michael Y.
Anaphylaxis leads to plaque rupture or erosion leading to acute myocardial infarction (type II) and acute coronary stentthrombosis (type III). Here we share a case of Kounis syndrome type I caused by an allergy caused by a Cryptopteran bite.
The United States has been way behind other nations in using drug-coated balloons (DCB) to treat coronary in-stent restenosis (ISR), but that’s about to change thanks to the FDA approval of Boston Scientific’s AGENT Drug-Coated Balloon. vs 12.3%) Stentthrombosis (0.0% vs. 24.0%) Target vessel myocardial infarction (6.4%
Upon removal of its retrieval hook, the filter's legs are intended to expand, forming a stent-like structure that is suitable for long-term residence in the human body.
BackgroundProcedural intravenous cangrelor has been proposed as an effective platelet inhibition strategy for stenting in acute ischemic stroke. Safety outcomes included rates of symptomatic intracranial hemorrhage, parenchymal hematoma type 2, petechial hemorrhage, and in‐stentthrombosis. 3.28];P=0.836). versus 0%;P=0.911).ConclusionCangrelor
Old ‘NSTEMI’ A history of coronary artery disease and a stent to the same territory further increases pre-test likelihood of acute coronary occlusion, including in-stentthrombosis. The patient had a history of ‘NSTEMI’ a decade prior, with an RCA stent. Does this change your interpretation?
That, it was possible to treat atherosclerotic coronary artery disease with an updated Andreas Grüntzig’s balloon alone, without the safety net and comfort of implanting a single stent. Three interactive cases were treated with the drug-coated balloon and all patients were same-day discharged.
I would expect that a stent would be placed. The angiogram showed an open artery with 95% stenosis and thrombosis and it was stented. I would expect TIMI-3 flow (normal flow, no persistent ischemia) with a culprit in the RCA (or possibly Circumflex).
Follow‐up data including aneurysm thromboembolic complication, hemorrhagic complication, new neurological deficit, aneurysm occlusion, and in‐stentthrombosis were also recorded.ResultsOne‐hundred and eighty patients were included in analysis, 18 of which were acutely ruptured.
7 The use of antiplatelet agents to prevent stentthrombosis, moderate- to high-dose statin therapy after acute coronary syndromes, or antihypertensive agents in asymptomatic patients may all be perceived by patients as not providing benefit because they may not feel the effects.8
Primary endpoint of systematic review and meta-analysis is the NACE (Net Adverse Cardiac Events) and secondary are MACE (Major Adverse Cardiac Events), mortality, bleedings, myocardial infarction and stentthrombosis. Subgroup analyses included studies using only ticagrelor-based regimens and three-months duration of DAPT.
All the patients were observed during their hospital stay for postprocedure in-hospital morbidity (pump failure, contrast-induced nephropathy, major bleeding, cerebrovascular accident/stroke, access site complications or stentthrombosis) and mortality. The mean BMI was 27.48±4.93
It is important to recognize that coronary thrombosis is dynamic , with spontaneous opening and lysing of the thrombus in the infarct-related artery (we all have endogenous tPA and plasmin to lyse thrombi). It was stented.
Introduction:Subacute stentthrombosis (ST) is related to high rates of cardiac reinfarction. Circulation, Volume 150, Issue Suppl_1 , Page A4137144-A4137144, November 12, 2024. We present a case of reinfarction from ST.
5,7 Neuro‐interventional procedures including carotid artery stenting have been reported as secondary prevention strategies in patients with recurrent strokes.5,7,8 5,7 Neuro‐interventional procedures including carotid artery stenting have been reported as secondary prevention strategies in patients with recurrent strokes.5,7,8
A man in his 70s with past medical history of hypertension, dyslipidemia, CAD s/p left circumflex stent 2 years prior presented to the ED with worsening intermittent exertional chest pain relieved by rest. The reappearance of de Winter's pattern caused by acute stentthrombosis: A case report. Am J Emerg Med. 2014;32:e5–e8.
The commonest causes of MINOCA include: atherosclerotic causes such as plaque rupture or erosion with spontaneous thrombolysis, and non-atherosclerotic causes such as coronary vasospasm (sometimes called variant angina or Prinzmetal's angina), coronary embolism or thrombosis, possibly microvascular dysfunction.
The operator documented thoughtful consideration of risks and benefits of stent placement. Technically, there was a very narrow landing zone for the stent, and missing this could result in "jailing" the LCx, which is ideally avoided. Unfortunately, a few hours later the patient complained of recurrent chest pain.
She was noted to have incidental left internal jugular (IJ) vein thrombosis for which anticoagulation was held in the setting of recent neurosurgical procedure and SAH. After the second treatment, she had improvement in speech and motor strength. Systolic blood pressure goal was gradually normalized.
Although the attending crews did not consider the ECG pathognomonic for occlusive thrombosis, they nonetheless considered the patient high-risk for ACS and implored him to reconsider. He was rushed to the Cath Lab where an LAD culprit lesion was stented. Here is the LAD after stent placement.
Repeat ECG while waiting for cath team, t = 56 min after arrival: It is getting worse Angiogram showed 99% acute proximal LAD thrombosis. It was opened and stented. The Cath lab was activated.
Background Drug-eluting stents (DESs) have become the gold standard of coronary angioplasty since their inception in 2002. vs 57.5%, p=0.010), a greater average number of stents implanted per patient (1.72±0.92 To date, no study has shown the superiority of one type of polymer compared with the other.
A mid-LAD culprit lesion was identified and stented. Cardiology felt her chest pain to be, most likely, the result of coronary supply-demand mismatch in the context of HCM endothelial remodeling (i.e. Type II MI), however decided to pursue coronary angiogram out of an abundance of caution. References Naidu, S.
Stone, MD Mount Sinai Health System tim.hodson Wed, 04/02/2025 - 15:26 March 31, 2025 Using intravascular imaging (IVI) to guide stent implantation during complex stenting procedures is safer and more effective for patients with severely calcified coronary artery disease than conventional angiography, the more commonly used technique.
Background Stentthrombosis (ST) is an uncommon but serious complication of stent implantation. Methods The analysis included patients who received stent placement for the index acute coronary syndrome (ACS). drug-eluting stent (DES) vs. bare-metal stent (BMS) and anticoagulant with rivaroxaban vs. placebo].
BackgroundStent thrombosis is a rare but deleterious event. In patients with signs of acute inflammatory activation (24.9%), PCI was associated with a significantly increased risk for stentthrombosis (hazard ratio, 2.89;P<0.00001), Journal of the American Heart Association, Ahead of Print. P<0.001).ConclusionsAn
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content